MacroGenics ALERT: Securities Fraud Lawsuit Could Allow Investors to Recover Losses; Block & Leviton Encourages Investors to Contact the Firm to Learn More

The lawsuit alleges that MacroGenics and its executives made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, MacroGenics revealed that the drug was significantly more dangerous than previously represented, leading to a 77% decline in MacroGenics' stock price. What should you do next? If you have non-public information about MacroGenics, you should consider assisting in our investigation or working with our attorneys to file a re ...